Inhibition of TNF-α Improves the Bladder Dysfunction That Is Associated With Type 2 Diabetes
- Zongwei Wang1,
- Zhiyong Cheng2,
- Vivian Cristofaro3,
- Jijun Li1,4,
- Xingyuan Xiao1,5,
- Pablo Gomez6,
- Rongbin Ge1,
- Edward Gong6,
- Klemen Strle7,
- Maryrose P. Sullivan3,
- Rosalyn M. Adam6,
- Morris F. White2 and
- Aria F. Olumi1⇓
- 1Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
- 2Division of Endocrinology, Howard Hughes Medical Institute, Children’s Hospital Boston, Harvard Medical School, Boston, Massachusetts
- 3Urology Research, Veterans Administration Boston Healthcare System, Harvard Medical School, Boston, Massachusetts
- 4Department of Integrative Medicine, Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai, China
- 5Department of Urology, Wuhan Union Hospital, Huazhong University of Science and Technology, Wuhan, China
- 6Urology Research Center, Children’s Hospital Boston, Harvard Medical School, Boston, Massachusetts
- 7Department of Medicine, Division of Allergy/Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
- Corresponding author: Aria F. Olumi, .
Diabetic bladder dysfunction (DBD) is common and affects 80% of diabetic patients. However, the molecular mechanisms underlying DBD remain elusive because of a lack of appropriate animal models. We demonstrate DBD in a mouse model that harbors hepatic-specific insulin receptor substrate 1 and 2 deletions (double knockout [DKO]), which develops type 2 diabetes. Bladders of DKO animals exhibited detrusor overactivity at an early stage: increased frequency of nonvoiding contractions during bladder filling, decreased voided volume, and dispersed urine spot patterns. In contrast, older animals with diabetes exhibited detrusor hypoactivity, findings consistent with clinical features of diabetes in humans. The tumor necrosis factor (TNF) superfamily genes were upregulated in DKO bladders. In particular, TNF-α was upregulated in serum and in bladder smooth muscle tissue. TNF-α augmented the contraction of primary cultured bladder smooth muscle cells through upregulating Rho kinase activity and phosphorylating myosin light chain. Systemic treatment of DKO animals with soluble TNF receptor 1 (TNFRI) prevented upregulation of Rho A signaling and reversed the bladder dysfunction, without affecting hyperglycemia. TNFRI combined with the antidiabetic agent, metformin, improved DBD beyond that achieved with metformin alone, suggesting that therapies targeting TNF-α may have utility in reversing the secondary urologic complications of type 2 diabetes.
This article contains Supplementary Data online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-1763/-/DC1.
- Received December 29, 2011.
- Accepted March 14, 2012.
- © 2012 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.